# A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

> **NCT07170787** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 104 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** IMM2510
- **BIOLOGICAL:** IMM01

## Key facts

- **NCT ID:** NCT07170787
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2029-02
- **Final completion:** 2029-07
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07170787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07170787, "A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07170787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*